Literature DB >> 1913655

Prognostic significance of argyrophilic nucleolar organizer regions in esophageal carcinoma.

M Morita1, H Kuwano, H Matsuda, S Moriguchi, K Sugimachi.   

Abstract

The argyrophilic nucleolar organizer region (AgNOR) of 100 cancer cells from biopsy specimens of esophageal squamous cell carcinomas in 98 surgically treated cases was examined, using a silver colloid staining technique on biopsy specimens. The number of AgNOR per nucleus (AgNOR number) was higher in the more advanced groups with regard to the length of the tumor (P less than 0.01), the depth of penetration (P less than 0.05), and lymph node metastasis (P less than 0.01). The survival of the patients with a high AgNOR number (greater than or equal to 6) was significantly poorer than those with either a medium range AgNOR number (4 less than or equal to-less than 6) (P less than 0.05) or a low AgNOR number (less than 4) (P less than 0.01). In the multivariate analysis including conventional clinicopathological factors, the AgNOR number was found to be one of the independent and significant variables (P less than 0.01). Because the AgNOR method is simple and can be applied to paraffin-embedded sections, the AgNOR number may provide potential benefit in the pretherapeutic assessment of malignant potentiality in esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913655

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Gallbladder cancer. A comparative study among clinicopathologic features, AgNORs, and DNA content analysis.

Authors:  J E Nishizawa-Takano; H Ayabe; K Hatano; H Yamaguchi; Y Tagawa
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

2.  Predictive value of argyrophilic nucleolar-organizer-region-associated proteins in bladder cancer, using cell-imprint preparations.

Authors:  M Masuda; Y Takano; M Iki; S Jinza; S Noguchi; Y Kubota; M Hosaka
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy.

Authors:  Y Shimada; M Imamura; I Shibagaki; H Tanaka; T Miyahara; M Kato; K Ishizaki
Journal:  Ann Surg       Date:  1997-08       Impact factor: 12.969

Review 4.  The nucleolus.

Authors:  H G Schwarzacher; F Wachtler
Journal:  Anat Embryol (Berl)       Date:  1993-12

5.  Argyrophilic nucleolar organizer regions as a prognostic indicator of laryngeal carcinomas.

Authors:  T Nakashima; G Yano; A Masuda; T Uemura; M Morita
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

6.  PCNA immunostaining combined with AgNOR staining in esophageal squamous cell carcinoma to identify patients with a poor prognosis.

Authors:  Y Morisaki; S Shima; Y Yoshizumi; Y Sugiura; S Tanaka; S Tamai
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

7.  Esophageal squamous cell carcinoma: pathology and prognosis.

Authors:  H Ide; T Nakamura; K Hayashi; T Endo; A Kobayashi; R Eguchi; F Hanyu
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

8.  Clinicopathological features and prognostic significance of nucleoside diphosphate kinase/nm23 gene product in human pancreatic exocrine neoplasms.

Authors:  S Nakamori; O Ishikawa; H Ohigashi; S Imaoka; Y Sasaki; M Kameyama; T Kabuto; H Furukawa; T Iwanakga; N Kimura
Journal:  Int J Pancreatol       Date:  1993-10

9.  Number of argyrophilic nucleolar organizer regions is a good indicator of lymph node metastasis in patients with esophageal carcinoma.

Authors:  M Ikeguchi; K Katano; A Oka; S Tsujitani; M Maeta; N Kaibara
Journal:  Langenbecks Arch Chir       Date:  1995

10.  A correlation of argyrophilic nucleolar organizer regions with prognoses in patients with maxillary sinus squamous cell carcinoma.

Authors:  M Miyaguchi; T Kawahara; S Sakai; H Kuwabara; H Sakamoto
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.